吉非替尼治疗非小细胞肺癌的作用机制及临床效果  

The Mechanism and Clinical Efficacy of Epidermal Growth Factor Receptor ( EGFR) Tyrosine Kinase Inhibitor Gefitinib

作　　者：吴艳丽 芦爽 WU Yanli;LU Shuang(Guangshui First People's Hospital,Guangshui,432700)

机构地区：[1]湖北省广水市第一人民医院,432700

出　　处：《实用癌症杂志》2018年第11期1882-1884,共3页The Practical Journal of Cancer

摘　　要：目的探究吉非替尼对于非小细胞肺癌的临床治疗效果及安全性。方法选取150例非小细胞肺癌患者,按照随机数字表法分为实验组与对照组,各75例。对照组给予多西他赛联合顺铂进行常规化疗,实验组给予吉非替尼进行表皮生长因子受体靶向治疗。结果实验组间质性肺炎发病率低于对照组;实验组不良反应发生率明显低于对照组。实验组患者病情控制率高于对照组(P <0. 05),对白细胞计数及Karnofsky评分的改善优于对照组。结论吉非替尼可较好地控制非小细胞肺癌患者的病情,改善患者的生存质量,并且降低并发间质性肺炎及其他不良反应的几率。Objective To explore the clinical efficacy and safety of Gefitinib for non-small cell lung cancer(NSCLC).Methods 150 patients suffered NSCLC were collected and were randomly assigned to the experimental group and the control group.The patients in control group were treated with docetaxel combined cis-platinum while the patients in experimental group were treated with gefitinib targeting EGFR.Results The morbidity of interstitial pneumonia and other adverse effects in the experimental group was obviously lower than the control group.The improvement of patients in the experimental group was obviously better than the control group(P<0.05).White cell count and karnofsky score improvment in the experiment group was better than the control group.Conclusion Gefitinib can obviously alleviate NSCLC and prolong the life of the patients.Furthermore,it can lower the morbidity of interstitial pneumonia and other adverse effects.

关 键 词：吉非替尼 非小细胞肺癌 常规化疗 

分 类 号：R734.2[医药卫生—肿瘤]